A Multi-center, Randomized, Double-blind, Placebo-controlled Phase I/II Trial to Compare the Safety, Tolerability and Immunogenicity of the Therapeutic THV01 Vaccination at 5.10E+6 TU (Transducing Unit) , 5.10E+7 TU (Transducing Unit) or 5.10E+8 TU (Transducing Unit) Doses to Placebo in HIV-1 Clade B Infected Patients Under Highly Active Antiretroviral Therapy (HAART)

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase I/II Trial to Compare the Safety, Tolerability and Immunogenicity of the Therapeutic THV01 Vaccination at 5.10E+6 TU (Transducing Unit) , 5.10E+7 TU (Transducing Unit) or 5.10E+8 TU (Transducing Unit) Doses to Placebo in HIV-1 Clade B Infected Patients Under Highly Active Antiretroviral Therapy (HAART)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs THV 01 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man
  • Sponsors THERAVECTYS
  • Most Recent Events

    • 08 Dec 2015 Planned end date changed from 1 Nov 2015 to 1 Mar 2019, as reported by ClinicalTrials.gov.
    • 08 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.
    • 18 Jul 2015 According to THERAVECTYS media release, detailed results from this trial were presented at the 2015 Towards an HIV Cure Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top